Healthcare Industry News: thrombin
News Release - December 6, 2007
Mary Ann Gray Elected to GTC Biotherapeutics Board of DirectorsFRAMINGHAM, Mass.--(HSMN NewsFeed)--GTC Biotherapeutics, Inc. ("GTC", Nasdaq: GTCB) announced that Mary Ann Gray, Ph.D. of Gray Strategic Advisors, LLC has been elected to its Board of Directors. GTC’s Board now has a total of eleven directors.
“We are very pleased to welcome Dr. Mary Ann Gray to our Board of Directors,” stated Geoffrey F. Cox, Ph.D., GTC’s Chairman of the Board and Chief Executive Officer. “Dr. Gray has established a reputation as an influential voice in the biotechnology and healthcare industry. Her extensive experience as an investor, analyst, consultant, and scientist will be a valuable contribution to our board.”
Background on Dr. Gray
Dr. Gray is President of Gray Strategic Advisors, LLC, a strategic planning and advisory firm for biotechnology companies. She also is a member of the boards of Telik, Inc., Dyax Corp., and Acadia Pharmaceuticals. Previously, Dr. Gray was Portfolio Manager of Federated Kaufmann Fund and was responsible for over $1 billion in health care investments. Dr. Gray has also been a senior biotechnology analyst at Raymond James & Associates, Warburg Dillon Read, and Kidder Peabody & Company. Dr. Gray served as a senior scientist at Schering-Plough Research and NeoRx Corporation.
Dr. Gray received her Bachelor of Science degree from the University of South Carolina and her Ph.D. in pharmacology from the University of Vermont. She was a postdoctoral associate at Northwestern University School of Medicine and Yale University School of Medicine.
Background on GTC
GTC Biotherapeutics develops, produces, and commercializes therapeutic proteins through transgenic animal technology. GTC obtained the first approval anywhere in the world for a transgenically produced protein when ATryn®, a recombinant form of human antithrombin, was approved by the European Commission for use in patients with hereditary antithrombin deficiency undergoing surgical procedures. ATryn® is undergoing a phase III clinical study in the hereditary antithrombin deficiency indication for the United States. Completion of ATryn®'s Biologics License Application is planned for the first half of 2008. GTC's intellectual property includes a patent in the United States through 2021 for the production of any therapeutic protein in the milk of any transgenic mammal. GTC's transgenic production platform is particularly well suited to enabling cost effective development of proteins that are difficult to express in traditional recombinant production systems as well as those that are required in large volumes. Additional information is available on the GTC web site, http://www.gtc-bio.com.
Source: GTC Biotherapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.